Report cover image

Clinical Trials - Impact of COVID-19 and Long COVID

Publisher GlobalData
Published May 29, 2023
Length 60 Pages
SKU # GBDT18034474

Description

Clinical Trials - Impact of COVID-19 and Long COVID


Summary

This report provides an overview of global COVID-19 clinical trials, long COVID clinical trials, and trials disrupted by COVID-19.

Scope
  • The clinical trials data used for these analyses were extracted from GlobalData’s Clinical Trials Database. The data was captured in the database as of April 12, 2023. The data was analyzed and segmented by COVID-19 trials, COVID-19 trials for vaccines and therapeutics, and long COVID trials. An analysis was also completed on non-COVID trials impacted due to the pandemic.
Reasons to Buy
  • Trends of COVID-19 trials through the years
  • Comparison of trials by phase, sponsor type and status
  • Geographic analysis
  • Focus on top sponsors for vaccine and therapeutic trials
  • Long COVID analysis
  • COVID-19 impact on trials

Table of Contents

60 Pages
Executive Summary
Introduction
Report Scope
Methodology
COVID-19 Cases & Deaths Continue but at a Lower Rate
COVID-19 Clinical Trials Analysis
COVID-19 Clinical Trials Starts per Month Continue to Decline
Single-Country COVID-19 Trials Dominate
Asia-Pacific Continues to Dominate Single-Country Trials
Europe Still Has the Most Multinational Clinical Trials
North America Has the Most Clinical Trial Sites
Slight Change in Order of US States for COVID-19 Sites
Phase II and Now Completed Trials Dominate the Landscape of COVID-19 Trials
Primary Endpoints Continue to Be Achieved
Low Accrual Rate Was the Primary Cause for Trial Termination
Low Accrual Rate Was the Primary Cause for Trial Termination by Sponsor Type
COVID-19 Clinical Trials for Vaccines & Therapeutics
The Amount of Vaccine COVID-19 Clinical Trials Changes Over Time
Therapeutic COVID-19 Trials Decline More
Phase II Has Most Trials for Vaccine & Therapeutic COVID-19 Clinical Trials
Vaccine & Therapeutic COVID-19 Clinical Trials See the Most Trials in Different Trial Statuses
Sinovac Biotech Still Top Industry Sponsor for Vaccine Trials
Finlay Vaccine Institute Is the Top Non-industry Vaccine Trial Sponsor
Sorrento Therapeutics Is Top Industry Sponsor for COVID-19 Therapeutics Trials
Universities Still Top Non-industry Sponsors
Long COVID Analysis
Attention Has Turned to Long COVID
Majority of Long COVID Trials Are Ongoing
North America Also Has Most Long COVID Sites
US and Florida Top Long COVID Sites by Country and State
A Wide Range of Sponsor Types for Long COVID Trials
Colchicine Is Top Drug Tested for Long COVID
Phase II Trial Completions Expected Most in Upcoming Long COVID Events
Impact of COVID-19 on Clinical Trials
Clinical Trials Disrupted Due to COVID-19
Central Nervous System Leads All Therapy Areas in Disrupted Trials
Where Is the Most Disruption of Clinical Trials?
Emory University Is Top Sponsor with Most Disruption
Resumed Clinical Trials Increasing
Increased Use of Decentralized Clinical Trials
Central Nervous System Utilizes DCTs the Most
The Top Industry Sponsor Using DCTs Is GlaxoSmithKline
University of Oxford and Duke University Top Non-industry Sponsors for DCTs
Telemedicine Is the Most Used DCT Component
More Real-World Evidence Used After the Pandemic
Key Findings
Appendix
List of Tables
Table 1: Total Number of COVID-19 cases and deaths
List of Figures
Figure 1: Total number of COVID-19 cases and deaths
Figure 2: Number of COVID-19 clinical trials by start date, by month
Figure 3: Number of COVID-19 clinical trials, by multinational versus single-country
Figure 4: Single-country COVID-19 clinical trials, by region and phase
Figure 5: Multinational COVID-19 clinical trials, by region and phase
Figure 6: COVID-19 clinical trial sites, by region
Figures 7 & 8: COVID-19 clinical trial sites, by country and state
Figures 9 & 10: Number of COVID-19 clinical trials, by phase and status
Figure 11: Endpoint status for completed COVID-19 clinical trials
Figure 12: Top reasons for terminated trials, by phase
Figure 13: Top reason for terminated trials, by sponsor type
Figure 14: COVID-19 vaccine clinical trials, by trial start date
Figure 15: COVID-19 therapeutic clinical trials, by trial start date
Figures 16 & 17: Vaccine & therapeutic COVID-19 clinical trials, by phase
Figures 18 & 19: Vaccine & therapeutic COVID-19 clinical trials, by status
Figure 20: Top industry sponsors for COVID-19 vaccine clinical trials
Figure 21: Top non-industry sponsors for COVID-19 vaccine clinical trials
Figure 22: Top industry sponsors for COVID-19 therapeutic clinical trials
Figure 23: Top non-industry sponsors for COVID-19 therapeutic clinical trials
Figure 24: Long COVID clinical trials, by trial start date
Figure 25: Long COVID clinical trials, by trial status
Figure 26: Long COVID clinical trial sites, by region
Figures 27 & 28: Long COVID clinical trial sites, by country and US state
Figure 29: Long COVID clinical trials by sponsor
Figure 30: Long COVID clinical trials by drug
Figure 31: Upcoming long COVID clinical trial events
Figure 32: Clinical trials disrupted due to COVID-19
Figure 33: Disrupted clinical trials, by therapy area
Figures 34 & 35: Disrupted clinical trials activities, by region and country
Figure 36: Disrupted clinical trials, by top sponsors
Figure 37: Resumed clinical trials after being disrupted due to COVID-19, by status
Figure 38: Decentralized clinical trials, by trial start date
Figure 39: Decentralized clinical trials, by therapy area
Figure 40: Top industry sponsors for decentralized clinical trials
Figure 41: Top non-industry sponsors for decentralized clinical trials
Figure 42: Telemedicine clinical trials by trial start year
Figure 43: Number of real-world-evidence trials, by trial end date

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us